PL2785693T3 - Arylodihydropirydynony i piperydynony jako inhibitory mgat2 - Google Patents

Arylodihydropirydynony i piperydynony jako inhibitory mgat2

Info

Publication number
PL2785693T3
PL2785693T3 PL12821212.3T PL12821212T PL2785693T3 PL 2785693 T3 PL2785693 T3 PL 2785693T3 PL 12821212 T PL12821212 T PL 12821212T PL 2785693 T3 PL2785693 T3 PL 2785693T3
Authority
PL
Poland
Prior art keywords
piperidinones
mgat2 inhibitors
dihydropyridinones
aryl
aryl dihydropyridinones
Prior art date
Application number
PL12821212.3T
Other languages
English (en)
Polish (pl)
Inventor
Huji Turdi
Jon J. Hangeland
R. Michael Lawrence
Dong Cheng
Saleem Ahmad
Wei Meng
Robert Paul Brigance
Pratik Devasthale
Guohua Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2785693T3 publication Critical patent/PL2785693T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C07F9/5352—Phosphoranes containing the structure P=C-
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12821212.3T 2011-12-02 2012-11-30 Arylodihydropirydynony i piperydynony jako inhibitory mgat2 PL2785693T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566039P 2011-12-02 2011-12-02
US13/688,584 US8791091B2 (en) 2011-12-02 2012-11-29 Aryl dihydropyridinone and piperidinone MGAT2 inhibitors

Publications (1)

Publication Number Publication Date
PL2785693T3 true PL2785693T3 (pl) 2016-11-30

Family

ID=48524439

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12821212.3T PL2785693T3 (pl) 2011-12-02 2012-11-30 Arylodihydropirydynony i piperydynony jako inhibitory mgat2

Country Status (34)

Country Link
US (8) US8791091B2 (enEXAMPLES)
EP (2) EP2785693B1 (enEXAMPLES)
JP (2) JP5806417B2 (enEXAMPLES)
KR (2) KR101666729B1 (enEXAMPLES)
CN (2) CN107266416B (enEXAMPLES)
AR (1) AR090041A1 (enEXAMPLES)
AU (1) AU2012345863B2 (enEXAMPLES)
BR (1) BR112014013228B1 (enEXAMPLES)
CA (1) CA2857689C (enEXAMPLES)
CL (1) CL2014001437A1 (enEXAMPLES)
CO (1) CO6990718A2 (enEXAMPLES)
CY (1) CY1118128T1 (enEXAMPLES)
DK (1) DK2785693T3 (enEXAMPLES)
EA (1) EA026367B1 (enEXAMPLES)
ES (2) ES2584070T3 (enEXAMPLES)
HR (1) HRP20161011T1 (enEXAMPLES)
HU (1) HUE030547T2 (enEXAMPLES)
IL (1) IL232727A (enEXAMPLES)
IN (1) IN2014CN03803A (enEXAMPLES)
MA (1) MA35753B1 (enEXAMPLES)
MX (1) MX355988B (enEXAMPLES)
MY (1) MY173478A (enEXAMPLES)
PE (1) PE20141307A1 (enEXAMPLES)
PH (1) PH12014501162A1 (enEXAMPLES)
PL (1) PL2785693T3 (enEXAMPLES)
PT (1) PT2785693T (enEXAMPLES)
RS (1) RS54985B1 (enEXAMPLES)
SG (2) SG11201402389PA (enEXAMPLES)
SI (1) SI2785693T1 (enEXAMPLES)
SM (1) SMT201600272B (enEXAMPLES)
TN (1) TN2014000238A1 (enEXAMPLES)
TW (1) TWI636044B (enEXAMPLES)
WO (1) WO2013082345A1 (enEXAMPLES)
ZA (1) ZA201404867B (enEXAMPLES)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791091B2 (en) * 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
US9604964B2 (en) 2012-11-16 2017-03-28 Bristol-Myers Squibb Company Dihydropyrazole GPR40 modulators
CA2891569A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
US9656963B2 (en) 2012-11-16 2017-05-23 Bristol-Myers Squibb Company Dihydropyrazole GPR40 modulators
HRP20161631T1 (hr) 2012-11-16 2017-01-13 Bristol-Myers Squibb Company Dihidropirazolni gpr40 modulatori
EP2925747B1 (en) 2012-11-29 2020-06-24 Merck Patent GmbH Azaquinazoline carboxamide derivatives
TW201534585A (zh) 2013-05-29 2015-09-16 必治妥美雅史谷比公司 二氫吡啶酮ｍｇａｔ２抑制劑
AU2015227142A1 (en) * 2014-03-07 2016-10-20 Bristol-Myers Squibb Company Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
NZ724890A (en) 2014-03-07 2019-11-29 Bristol Myers Squibb Co Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
ES2666569T3 (es) 2014-06-11 2018-05-07 Bristol-Myers Squibb Company Piridinonas sustituidas como inhibidores de MGAT2
KR101750392B1 (ko) * 2014-12-03 2017-06-26 한국도로공사 교량 점검용 거더의 유도 레일장치 및 그 교량 점검장치
WO2017069224A1 (ja) * 2015-10-22 2017-04-27 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有するスピロ環誘導体
WO2017110841A1 (ja) * 2015-12-21 2017-06-29 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
JP2020158390A (ja) * 2017-06-20 2020-10-01 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体およびそれらを含有する医薬組成物
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
CN107759498A (zh) * 2017-11-08 2018-03-06 南京大学 抗肿瘤化合物、制备方法及其用途
WO2020145369A1 (ja) 2019-01-11 2020-07-16 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体
US12240855B2 (en) 2019-03-06 2025-03-04 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3073838A (en) * 1963-01-15 Derivatives of hydkogenateb pyridones
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US8344132B2 (en) * 2005-06-22 2013-01-01 BioCryst Pharmaceticals, Inc. Methods for the preparation of 9-deazapurine derivatives
EP2078719A4 (en) * 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION
WO2008093464A1 (ja) 2007-01-31 2008-08-07 Banyu Pharmaceutical Co., Ltd. Mgat2遺伝子改変動物
CA2751244A1 (en) 2009-02-23 2010-08-26 Msd K.K. Pyrimidin-4(3h)-one derivatives
TW201300358A (zh) 2011-03-14 2013-01-01 大正製藥股份有限公司 含氮縮合雜環化合物
US8791091B2 (en) * 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
NZ724890A (en) 2014-03-07 2019-11-29 Bristol Myers Squibb Co Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
AU2015227142A1 (en) 2014-03-07 2016-10-20 Bristol-Myers Squibb Company Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders

Also Published As

Publication number Publication date
TW201329048A (zh) 2013-07-16
CN104080768A (zh) 2014-10-01
NZ626751A (en) 2016-07-29
ES2699905T3 (es) 2019-02-13
SMT201600272B (it) 2016-08-31
IL232727A (en) 2017-09-28
US20130143843A1 (en) 2013-06-06
MA35753B1 (fr) 2014-12-01
JP2016028059A (ja) 2016-02-25
AU2012345863A1 (en) 2014-07-24
US10966967B2 (en) 2021-04-06
BR112014013228B1 (pt) 2021-02-17
DK2785693T3 (en) 2016-09-05
CO6990718A2 (es) 2014-07-10
KR101666729B1 (ko) 2016-10-17
AU2012345863B2 (en) 2017-07-27
EA026367B1 (ru) 2017-03-31
CA2857689A1 (en) 2013-06-06
US20200281905A1 (en) 2020-09-10
KR20140099519A (ko) 2014-08-12
MY173478A (en) 2020-01-28
WO2013082345A9 (en) 2014-09-25
IL232727A0 (en) 2014-08-03
TN2014000238A1 (en) 2015-09-30
CL2014001437A1 (es) 2014-10-03
CN104080768B (zh) 2017-05-24
US8791091B2 (en) 2014-07-29
HUE030547T2 (en) 2017-05-29
JP5806417B2 (ja) 2015-11-10
SG10201607722TA (en) 2016-11-29
ZA201404867B (en) 2017-04-26
EP2785693B1 (en) 2016-05-18
US9663466B2 (en) 2017-05-30
JP6078601B2 (ja) 2017-02-08
US20160031816A1 (en) 2016-02-04
RS54985B1 (sr) 2016-11-30
MX2014006318A (es) 2014-06-23
PE20141307A1 (es) 2014-10-01
SI2785693T1 (sl) 2016-09-30
HK1197231A1 (zh) 2015-01-09
US9187424B1 (en) 2015-11-17
EP3053912A1 (en) 2016-08-10
JP2015500237A (ja) 2015-01-05
CA2857689C (en) 2016-06-21
BR112014013228A2 (pt) 2017-06-13
WO2013082345A8 (en) 2014-01-23
CN107266416A (zh) 2017-10-20
CY1118128T1 (el) 2017-06-28
US10369140B2 (en) 2019-08-06
US20180133198A1 (en) 2018-05-17
TWI636044B (zh) 2018-09-21
PT2785693T (pt) 2016-07-29
US10695328B2 (en) 2020-06-30
IN2014CN03803A (enEXAMPLES) 2015-10-16
EA201491079A1 (ru) 2014-09-30
US20150315144A1 (en) 2015-11-05
AR090041A1 (es) 2014-10-15
MX355988B (es) 2018-05-08
HRP20161011T1 (hr) 2016-10-07
US9901572B2 (en) 2018-02-27
WO2013082345A1 (en) 2013-06-06
CN107266416B (zh) 2020-07-10
ES2584070T3 (es) 2016-09-23
PH12014501162B1 (en) 2014-08-11
SG11201402389PA (en) 2014-09-26
US20210161869A1 (en) 2021-06-03
EP2785693A1 (en) 2014-10-08
PH12014501162A1 (en) 2014-08-11
US20190314346A1 (en) 2019-10-17
KR20160120797A (ko) 2016-10-18
EP3053912B1 (en) 2018-09-12
US20170216263A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
ZA201404867B (en) Aryl dihydropyridinones and piperidinones as mgat2 inhibitors
IL252108A0 (en) cdk inhibitors
IL233454A0 (en) Bromodomain inhibitors
IL230917A0 (en) 1dyrk inhibitors and uses thereof
PL2769980T3 (pl) Pochodna pirazolochinoliny jako inhibitory PDE9
IL228707A0 (en) History of tetrahydroquinolines used as bromodomain inhibitors
ZA201401113B (en) COMPOUND AND COMPOSISTIONS AS c-KIT KINASE INHIBITORS
EP2736330A4 (en) COMPOUNDS AND METHODS
EP2747560A4 (en) CONNECTIONS AND METHODS
EP2736332A4 (en) CONNECTIONS AND METHODS
EP2697309A4 (en) POLYPHOSPHONATE AND COPOLYPHOSPHONATE ADDITIVE MIXTURES
EP2736329A4 (en) COMPOUNDS AND METHODS
IL235919A0 (en) inhibitors of fbxo3
IL230746A0 (en) 2-aldh inhibitors in the treatment of addiction
GB201120474D0 (en) Inhibitors
GB201018597D0 (en) Inhibitors
GB201220458D0 (en) Novel FAP inhibitors
GB201200705D0 (en) Novel fap inhibitors
GB201104399D0 (en) Novel inhibitors